RT Journal Article
T1 Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database
A1 Campos-Balea, Begoña
A1 de Castro Carpeño, Javier
A1 Massutí, Bartomeu
A1 Vicente-Baz, David
A1 Pérez Parente, Diego
A1 Ruiz-Gracia, Pedro
A1 Crama, Leonardo
A1 Cobo Dols, Manuel
K1 Lung adenocarcinoma
K1 Metastasis
K1 Non-small cell lung cancer
K1 Overall survival
K1 Prognostic factor
K1 Adenocarcinoma del pulmón
K1 Metástasis neoplásica
K1 Carcinoma de pulmón de células no pequeñas
K1 Pronóstico
AB Background: Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for overall survival (OS) in patients with stage IV lung ADC in real-world clinical practice.Methods: Patients were selected from the Surveillance Epidemiology and End Results (SEER) database. Chi-square bivariate analysis was used for the association of binary qualitative variables. A multivariate Cox regression analysis was performed to determine the impact of these prognostic factors on OS.Results: A total of 46 030 patients were included (51.3% men, mean age 67.03 ± 11.6), of whom 41.3% presented with metastases in bone, 28.9% in brain, 17.1% in liver and 31.8% in lung. Patients with liver metastases presented with two or more metastatic sites more frequently than patients without liver metastases (P < 0.001). Male sex (HR 0.78, 95% CI: 0.76-0.80), age ≥ 65 years (HR 1.37, 95% CI: 1.33-1.40), lack of family support (HR 0.80, 95% CI: 0.78-0.81) and presence of liver (HR 1.45, 95% CI: 1.40-1.50), bone (HR 1.21, 95% CI: 1.18-1.24) or brain metastases (HR 1.18, 95% CI: 1.15-1.21) were identified as poor prognostic factors for OS. Patients with liver metastasis showed the highest hazard ratio value (P < 0.001).Conclusions: The presence of liver metastases was the worst prognostic factor for patients with metastatic lung ADC. This factor should be considered as a stratification factor for future studies evaluating new cancer treatments including immunotherapy.
PB China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
SN 1759-7706
YR 2020
FD 2020
LK http://hdl.handle.net/10668/3848
UL http://hdl.handle.net/10668/3848
LA en
NO Campos-Balea B, de Castro Carpeño J, Massutí B, Vicente-Baz D, Pérez Parente D, Ruiz-Gracia P, et al. Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database. Thorac Cancer. 2020 Nov;11(11):3357-3364
DS RISalud
RD Apr 10, 2025